Kamada Ltd. (NASDAQ:KMDA – Get Rating) – Analysts at HC Wainwright issued their Q1 2023 earnings estimates for shares of Kamada in a note issued to investors on Thursday, March 16th. HC Wainwright analyst A. Fein anticipates that the biotechnology company will post earnings per share of $0.04 for the quarter. HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for Kamada’s current full-year earnings is $0.33 per share. HC Wainwright also issued estimates for Kamada’s Q2 2023 earnings at $0.03 EPS, Q3 2023 earnings at $0.03 EPS, Q4 2023 earnings at $0.03 EPS and FY2027 earnings at $0.70 EPS.
Separately, StockNews.com assumed coverage on shares of Kamada in a research report on Thursday. They set a “buy” rating on the stock.
Kamada Stock Performance
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in the business. Phoenix Holdings Ltd. raised its stake in Kamada by 2.2% in the 4th quarter. Phoenix Holdings Ltd. now owns 2,105,523 shares of the biotechnology company’s stock valued at $8,443,000 after acquiring an additional 45,612 shares during the period. Altshuler Shaham Ltd boosted its holdings in shares of Kamada by 7.2% during the third quarter. Altshuler Shaham Ltd now owns 919,697 shares of the biotechnology company’s stock worth $4,630,000 after acquiring an additional 61,703 shares during the period. Vanguard Group Inc. lifted its holdings in Kamada by 7.3% during the 3rd quarter. Vanguard Group Inc. now owns 864,789 shares of the biotechnology company’s stock worth $3,900,000 after purchasing an additional 58,705 shares during the last quarter. Wells Fargo & Company MN boosted its stake in Kamada by 4.5% in the 4th quarter. Wells Fargo & Company MN now owns 513,876 shares of the biotechnology company’s stock valued at $2,000,000 after purchasing an additional 22,013 shares during the period. Finally, Arete Wealth Advisors LLC acquired a new position in Kamada in the 4th quarter valued at $949,970,200,000. 15.29% of the stock is currently owned by institutional investors.
Kamada Ltd. is a biopharmaceutical company, which focuses on specialty plasma-derived therapeutic. It operates through the Proprietary Products and Distribution segments. The Proprietary Products segment covers the development, manufacture, and sale of plasma-derived protein therapeutics products. The Distribution segment covers the drug products in Israel, which are manufactured by third parties.
- Get a free copy of the StockNews.com research report on Kamada (KMDA)
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
- Europe Raises Interest Rates, Should the Fed Follow?
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.